Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 8/20 | 0.61 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935062 | 0.90 | PNP (0.70) | PNPTHRBKDM4EMEN1ALDH1A1 | |
| SCHEMBL9806967 | 0.85 | PNP (0.63) | PNPTHRBKDM4EMEN1ALDH1A1 | |
| SCHEMBL350396 | 0.83 | PNP (0.61) | PNPTHRBKDM4EMEN1ALDH1A1 | |
| SCHEMBL667795 | 0.83 | PNP (0.61) | PNPTHRBKDM4EMEN1ALDH1A1 | |
| SCHEMBL9960811 | 0.82 | PNP (0.71) | PNPTHRBKDM4EMEN1ALDH1A1 | |
| SCHEMBL15743133 | 0.82 | PNP (0.59) | PNPTHRBKDM4EMEN1ALDH1A1 | |
| SCHEMBL8196747 | 0.81 | PNP (0.58) | PNPTHRBKDM4EMEN1ALDH1A1 | |
| SCHEMBL6272728 | 0.81 | PNP (0.58) | PNPTHRBKDM4EMEN1ALDH1A1 | |
| SCHEMBL6266584 | 0.80 | PNP (0.56) | PNPTHRBKDM4EMEN1ALDH1A1 | |
| SCHEMBL21314870 | 0.80 | PNP (0.56) | PNPTHRBKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM | 2023-02-09 | — | — | US | disclosed |
| US-20200109362-A1 | METHODS FOR CELL PROLIFERATION AND TOXICITY TESTING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-04-09 | — | — | US | disclosed |
| US-20180147178-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL | DELMAR PHARMACEUTICALS INC (CA) | 2018-05-31 | — | — | US | disclosed |
| CN-107903267-A | A kind of compound and preparation method and application of the coupling of azo aryl nitrogen mustard chlorethylnitrosourea | 北京工业大学 | 2018-04-13 | — | — | CN | disclosed |
| US-9901563-B2 | Compositions to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol | DELMAR PHARMACEUTICALS, INC. (CA) | 2018-02-27 | — | — | US | disclosed |
| CN-107722010-A | A kind of hypoxemia activation chlorethylnitrosourea containing nitroimidazole group and its preparation method and application | 北京工业大学 | 2018-02-23 | — | — | CN | disclosed |
| WO-2017223254-A1 | METHODS FOR CELL PROLIFERATION AND TOXICITY TESTING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-12-28 | — | — | WO | disclosed |
| CN-105503874-B | Hypoxemia activates joint chloroethylnitrosoureas compound and preparation method and application | 北京工业大学 | 2017-10-27 | — | — | CN | disclosed |
| CN-105367573-B | AGT protein inhibitors, its preparation method and application | 北京工业大学 | 2017-07-14 | — | — | CN | disclosed |
| US-20160346231-A1 | Disulfiram Compositions and Treatments for Brain Tumors | TEXAS TECH UNIVERSITY SYSTEM | 2016-12-01 | — | — | US | disclosed |
| EP-0702683-B1 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER REC TECH LTD (GB) | 2003-09-17 | — | — | EP | disclosed |
| EP-0910246-A4 | USE OF MUTANT ALKYLTRANSFERASES FOR GENE THERAPY TO PROTECT FROM TOXICITY OF THERAPEUTIC ALKYLATING AGENTS | PENN STATE RES FOUND (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20020198264-A1 | Methoxyamine combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2002-12-26 | — | — | US | disclosed |
| US-6465448-B1 | TREATING TUMORS RESISTANT TO TEMOZOLOMIDE ALONE | CASE WESTERN RESERVE UNIVERSITY | 2002-10-15 | — | — | US | disclosed |
| WO-2001012199-A2 | METHOXYAMINE POTENTIATION OF TEMOZOLOMIDE ANTI-CANCER ACTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-1999025386-A1 | delta-O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE TRANSFER FOR O6-BENZYLGUANINE AND (N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA) RESISTANCE | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0910246-A1 | USE OF MUTANT ALKYLTRANSFERASES FOR GENE THERAPY TO PROTECT FROM TOXICITY OF THERAPEUTIC ALKYLATING AGENTS | THE PENN STATE RESEARCH FOUNDATION (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997035477-A1 | USE OF MUTANT ALKYLTRANSFERASES FOR GENE THERAPY TO PROTECT FROM TOXICITY OF THERAPEUTIC ALKYLATING AGENTS | THE PENN STATE RESEARCH FOUNDATION (US) | 1997-10-02 | — | — | WO | disclosed |
| EP-0702683-A1 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-03-27 | — | — | EP | disclosed |
| WO-1994029312-A1 | O6-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | MGMT, SHMT2, SHMT1 | PNP 1267/4885THRB 3282/4885KDM4E 1149/4885 |
| US-20160346231-A1 | Disulfiram Compositions and Treatments for Brain Tumors | MGMT, NNMT, GNMT | PNP 1264/4885THRB 2641/4885KDM4E 618/4885 |
| US-20180147178-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL | DDOST, DAD1, B3GAT3 | PNP 1702/4885THRB 3996/4885KDM4E 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.